Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
76.76 USD | +2.09% | -1.06% | -3.56% |
Financials (USD)
Sales 2024 * | 376M | Sales 2025 * | 671M | Capitalization | 3.57B |
---|---|---|---|---|---|
Net income 2024 * | -233M | Net income 2025 * | -23M | EV / Sales 2024 * | 9.37 x |
Net cash position 2024 * | 46.33M | Net cash position 2025 * | 72.22M | EV / Sales 2025 * | 5.21 x |
P/E ratio 2024 * |
-15.9
x | P/E ratio 2025 * |
-202
x | Employees | 569 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.63% |
Latest transcript on Axsome Therapeutics, Inc.
1 day | +2.09% | ||
1 week | -1.06% | ||
Current month | +4.07% | ||
1 month | +7.04% | ||
3 months | -8.62% | ||
6 months | +15.85% | ||
Current year | -3.56% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 12-01-11 | |
Nick Pizzie
DFI | Director of Finance/CFO | 49 | 18-05-15 |
Mark Jacobson
COO | Chief Operating Officer | 40 | 14-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Saad
BRD | Director/Board Member | 54 | 14-11-30 |
Susan Mahony
BRD | Director/Board Member | 59 | 23-10-10 |
Roger Jeffs
BRD | Director/Board Member | 62 | 14-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.26% | 0 M€ | 0.00% | - | |
0.14% | 234 M€ | +11.93% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 76.76 | +2.09% | 481,391 |
24-05-24 | 75.19 | +1.36% | 377,246 |
24-05-23 | 74.18 | -3.40% | 439,503 |
24-05-22 | 76.79 | -1.70% | 683,494 |
24-05-21 | 78.12 | +0.70% | 466,718 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.56% | 3.57B | |
-1.64% | 90.28B | |
-1.97% | 39.5B | |
-15.47% | 31.71B | |
+61.28% | 26.41B | |
-22.81% | 14.34B | |
-8.82% | 12.89B | |
-11.77% | 11.8B | |
-45.97% | 10.95B | |
+3.30% | 8.85B |
- Stock Market
- Equities
- AXSM Stock